Canine OA

GALLIPRANT CAN BE USED FOR CANINE OSTEOARTHRITIS (OA) FROM FIRST DIAGNOSIS AND FOR AS LONG AS NEEDED*

Galliprant (grapiprant) is a first-in-class prostaglandin receptor antagonist (PRA), a piprant class, non-COX inhibiting NSAID. It specifically targets the EP4 receptor, the primary mediator of canine OA pain.1

  • Galliprant does not interfere with homeostatic mechanisms mediated through other receptors1,2

* As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the vet.

Galliprant – a mode of action unlike any other

TREATMENT SUCCESS SEEN BY OWNERS, CONFIRMED BY VETS3

Galliprant treatment resulted in statistically significant improvements in pain interference and pain severity scores compared to placebo on days 7, 14, 21 and 28**(P ≤0.05 for all).3

  • Prospective, randomized, masked, placebo-controlled, 16-site study
  • Galliprant dosed at 2mg/kg once daily for 28 days
  • 285 dogs enrolled
  • Dogs receiving Galliprant were 2 to 16.75 years old, weighing 4 to 59.5 kg
  • Measured in the field study through a validated owner assessment: Canine Brief Pain Inventory (CBPI)*** on days 0, 7, 14, 21, 28
  • Veterinary assessment (total orthopedic scores) were significantly better in dogs treated with Galliprant vs. placebo at each visit in the study
  • Improvements continued throughout the study period

** Primary study endpoint

*** The CBPI is a validated questionnaire that asks dog owners four questions about the severity of pain evident in a dog (the pain severity score) and six questions about how pain interferes with a dog’s activity level (the pain interference score). The questionnaire also has one overall impression score and is useful in detecting changes in a dog’s condition that result from intervention (e.g., medication, surgery).

Most dogs can be dosed once a day with a whole or half tablet

Galliprant dosing table

†Galliprant should be dosed on an empty stomach.

Treat with Galliprant from the first diagnosis of canine OA for as long as needed*

Mode of action targets canine OA pain while reducing the impact on GI, kidney and liver homeostasis.1,2

  • Galliprant was well tolerated over 9 months at doses equivalent to 15x the target dose in the target animal safety study4
  • Suitable for dogs as young as 9 months of age and older
Incorporate Galliprant into your canine OA pain protocol today
To find out more, contact your Elanco representative or visit MyElanco for full details about Galliprant.

Indication

Galliprant is indication for the treatment of pain associated with mild to moderate osteoarthritis in dogs.

Important Safety Information

Name of the veterinary medicinal product: Galliprant 20 mg, 60 mg, and 100 mg tablets for dogs. Indication: Galliprant is indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Side effects, precautions, warnings and contraindications: Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contraindications. Storage: Do not store above 30°C. Any half tablets should be stored in the bottle. In order to avoid any accidental ingestion, store tablets out of reach of animals.

Galliprant contains grapiprant. Legal category POM-V (UK) POM (IE).

Further information is available from the Summary of Product Characteristics or datasheet. Advice should always be sought from the medicine prescriber. Information on this veterinary medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu. For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco Animal Health, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, United Kingdom.

Use medicines responsibly www.noah.co.uk/responsible (UK); www.apha.ie (IE).

LATEST NEWS

Be the first to hear about the latest news on Galliprant. For those in the UK, sign up to MyElanco for full product details and to get email updates. For those in Ireland, please complete this form.